Genmab A/S

As of June 30, 2026, Genmab A/S carries a market capitalization of 14.41B, placing it among publicly traded companies globally. Its enterprise value stands at 17.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genmab A/S's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Genmab A/S has 61.44M shares outstanding.

As of June 30, 2026, Genmab A/S trades at a trailing price-to-earnings ratio of 21.05. The price-to-sales ratio is 4.01, and the price-to-book ratio stands at 2.76.

As of June 30, 2026, Genmab A/S trades at an EV/EBITDA multiple of 17.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Genmab A/S trades at an EV/FCF ratio of 18.36, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 17.71B versus a market cap of 14.41B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Genmab A/S maintains a current ratio of 2.46, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 88.52, indicating elevated leverage, while an interest coverage ratio of 4.33 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Genmab A/S posted a return on equity (ROE) of 14.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.15 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.30, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.25, useful for judging operating efficiency across full business cycles. The company generates approximately 1.23M in revenue per employee across its workforce of 2,942.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 18.58 indicates how many times Genmab A/S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Genmab A/S recorded 103.29M in income tax expense. That works out to an effective tax rate of 13.02, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 793.02M, leaving 689.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Genmab A/S's stock has gained approximately 39.44% over the past 52 weeks. The 50-day moving average sits at 304.34, while the 200-day moving average is 256.85.

Over the twelve months ended June 30, 2026, Genmab A/S generated 3.62B in revenue and converted that into 689.74M in net income, yielding earnings per share of 10.82. EBITDA reached 1.02B, while operating income came in at 1.17B.

As of June 30, 2026, Genmab A/S holds 1.32B in cash and equivalents against 4.62B in total debt, resulting in a net debt position of 3.18B. Total book value stands at 5.21B, with working capital of 1.45B providing operational flexibility.

Genmab A/S produced 779.89M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.13M in capital expenditures, free cash flow totaled 759.76M - equivalent to 12.27 per share.

Over the twelve months ended June 30, 2026, Genmab A/S posted a gross margin of 93.03, reflecting its pricing power and cost economics. The operating margin of 32.29 and net profit margin of 19.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 5.08, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -30.11, meaning Genmab A/S raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Genmab A/S has an Altman Z-Score of 6.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.